Pros and Cons: Usage of organs from donors infected with hepatitis C virus - Revision in the direct-acting antiviral era

Journal of Hepatology

Volumn 64, Issue 1, 2016, Pages 226-231

  Coilly, Audrey ^a,b,c   Samuel, Didier ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

Author keywords

Extended criteria donors; Hepatitis C recurrence; High risk donors; Liver transplantation; Transplant survival

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; DIRECT ACTING ANTIVIRAL AGENT; LEDIPASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; KIDNEY TRANSPLANTATION; LIVER FIBROSIS; LIVER TRANSPLANTATION; ORGAN DONOR; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS TRANSMISSION; DONOR; TRANSMISSION;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; TISSUE DONORS; WAITING LISTS;

EID: 84961839403     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.09.002     Document Type: Note

References (47)

1. J.M. Sanchez-Tapias, and J. Rodes Dilemmas of organ transplantation from anti-HCV-positive donors Lancet 345 1995 469 470
2. A. Coilly, B. Roche, J.C. Duclos-Vallee, and D. Samuel Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals Liver Int 35 2015 44 50
3. A. Rana, A. Gruessner, V.G. Agopian, Z. Khalpey, I.B. Riaz, B. Kaplan, and et al. Survival benefit of solid-organ transplant in the United States JAMA Surg 150 2015 252 259
4. Annual Review of the Biomedicine Agency. < http://wwwagence-biomedecinefr/annexes/bilan2013/donnees/organes/05-foie/synthesehtm >, 2013.
5. P. Bruzzone A preliminary European study on extended-criteria liver donation and transplant recipient consent Transplant Proc 44 2012 1857 1858
6. E. Cholongitas, G.V. Papatheodoridis, and A.K. Burroughs Liver grafts from anti-hepatitis B core positive donors: a systematic review J Hepatol 52 2010 272 279
7. EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 60 2014 392 420
8. B.J. Pereira, and A.S. Levey Hepatitis C infection in cadaver organ donors: strategies to reduce transmission of infection and prevent organ waste Pediatr Nephrol 9 1995 S23 S28
9. Annual Review of the Biomedicine Agency. < http://wwwagence-biomedecinefr/annexes/bilan2010/donnees/organes/11-bilan/synthese >, 2011.
10. A.K. Mandal, E.S. Kraus, M. Samaniego, R. Rai, S.L. Humphreys, L.E. Ratner, and et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors Clin Transplant 14 2000 391 396
11. L.M. Kucirka, H. Sarathy, P. Govindan, J.H. Wolf, T.A. Ellison, L.J. Hart, and et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis Am J Transplant 11 2011 1188 1200
12. A. Suryaprasad, S.V. Basavaraju, S.N. Hocevar, N. Theodoropoulos, R.A. Zuckerman, T. Hayden, and et al. Transmission of hepatitis C virus from organ donors despite nucleic acid test screening Am J Transplant 15 2015 1827 1835
13. R. Ballarin, A. Cucchetti, M. Spaggiari, R. Montalti, F. Di Benedetto, S. Nadalin, and et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study Transplantation 91 2011 1265 1272
14. J.G. O'Leary, M.A. Neri, J.F. Trotter, G.L. Davis, and G.B. Klintmalm Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined Transpl Int 25 2012 825 829
15. C. Meffre, Y. Le Strat, E. Delarocque-Astagneau, F. Dubois, D. Antona, J.M. Lemasson, and et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors J Med Virol 82 2010 546 555
16. S.N. Natov Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 2: hepatitis C virus) Transpl Infect Dis 4 2002 124 131
17. D. Marelli, J. Bresson, H. Laks, B. Kubak, G. Fonarow, F.C. Tsai, and et al. Hepatitis C-positive donors in heart transplantation Am J Transplant 2 2002 443 447
18. J.E. Everhart, Y. Wei, H. Eng, M.R. Charlton, D.H. Persing, R.H. Wiesner, and et al. Recurrent and new hepatitis C virus infection after liver transplantation Hepatology 29 1999 1220 1226
19. J. Grebely, M. Prins, M. Hellard, A.L. Cox, W.O. Osburn, G. Lauer, and et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine Lancet Infect Dis 12 2012 408 414
20. X. Fan, D.M. Lang, Y. Xu, A.C. Lyra, K. Yusim, J.E. Everhart, and et al. Liver transplantation with hepatitis C virus-infected graft: interaction between donor and recipient viral strains Hepatology 38 2003 25 33
21. H.E. Vargas, T. Laskus, L.F. Wang, R. Lee, M. Radkowski, F. Dodson, and et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts Gastroenterology 117 1999 149 153
22. M.I. Aeder, C.F. Shield, G.E. Tegtmeier, W. Bayer, A.M. Luger, P.W. Nelson, and et al. Incidence and clinical impact of hepatitis C virus-positive donors in cadaveric transplantation Transplant Proc 25 1993 1469 1471
23. D.C. Mulligan, R.M. Goldstein, J.S. Crippin, M.S. Abouljoud, M.F. Levy, B.S. Husberg, and et al. Use of anti-hepatitis C virus seropositive organs in liver transplantation Transplant Proc 27 1995 1204 1205
24. G. Shah, A.J. Demetris, W. Irish, J. Scheffel, L. Mimms, and D.H. Van Thiel Frequency and severity of HCV infection following orthotopic liver transplantation. Effect of donor and recipient serology for HCV using a second generation ELISA test J Hepatol 18 1993 279 283
25. M. Torres, D. Weppler, K.R. Reddy, and A. Tzakis Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients Gastroenterology 117 1999 1253
26. C. Feray, D. Shouval, and D. Samuel Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients? Gastroenterology 117 1999 263 265
27. C.E. Marroquin, G. Marino, P.C. Kuo, J.S. Plotkin, V.K. Rustgi, A.D. Lu, and et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers Liver Transpl 7 2001 762 768
28. E. Velidedeoglu, N.M. Desai, L. Campos, K.M. Olthoff, A. Shaked, F. Nunes, and et al. The outcome of liver grafts procured from hepatitis C-positive donors Transplantation 73 2002 582 587
29. A.P. Khapra, K. Agarwal, M.I. Fiel, N. Kontorinis, S. Hossain, S. Emre, and et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts Liver Transpl 12 2006 1496 1503
30. A. Ricchiuti, A. Brunati, S. Mirabella, A. Pierini, A. Franchello, and M. Salizzoni Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience Transplant Proc 37 2005 2569 2570
31. E. Alvaro, M. Abradelo, A. Fuertes, A. Manrique, F. Colina, C. Alegre, and et al. Liver transplantation from anti-hepatitis C virus-positive donors: our experience Transplant Proc 44 2012 1475 1478
32. S. Saab, R.M. Ghobrial, A.B. Ibrahim, G. Kunder, F. Durazo, S. Han, and et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis Am J Transplant 3 2003 1167 1172
33. G. Testa, R.M. Goldstein, G. Netto, O. Abbasoglu, B.K. Brooks, M.F. Levy, and et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors Transplantation 65 1998 925 929
34. R.M. Ghobrial, R. Steadman, J. Gornbein, C. Lassman, C.D. Holt, P. Chen, and et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients Ann Surg 234 2001 384 393 Discussion 393-384
35. P.G. Northup, C.K. Argo, D.T. Nguyen, M.A. McBride, S.C. Kumer, T.M. Schmitt, and et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis Transpl Int 23 2010 1038 1044
36. N.A. Terrault, M.E. Roland, T. Schiano, L. Dove, M.T. Wong, F. Poordad, and et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection Liver Transpl 18 2012 716 726
37. M. Hoare, W.T. Gelson, S.M. Rushbrook, M.D. Curran, T. Woodall, N. Coleman, and et al. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection Hepatology 48 2008 1737 1745
38. J.C. Lai, J.G. O'Leary, J.F. Trotter, E.C. Verna, R.S. Brown Jr, R.T. Stravitz, and et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study Liver Transpl 18 2012 532 538
39. A. Coilly, B. Roche, and D. Samuel Current management and perspectives for HCV recurrence after liver transplantation Liver Int 33 2013 56 62
40. M. Charlton, E. Gane, M.P. Manns, R.S. Brown Jr, M.P. Curry, P.Y. Kwo, and et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation Gastroenterology 148 2015 108 117
41. X. Forns, M. Charlton, J. Denning, J.G. McHutchison, W.T. Symonds, D. Brainard, and et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation Hepatology 61 2015 1485 1494
42. P.Y. Kwo, P.S. Mantry, E. Coakley, H.S. Te, H.E. Vargas, R. Brown Jr, and et al. An interferon-free antiviral regimen for HCV after liver transplantation N Engl J Med 371 2014 2375 2382
43. V. Leroy, J. Dumortier, A. Coilly, M. Sebagh, C. Fougerou-Leurent, S. Radenne, and et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation Clin Gastroenterol Hepatol 13 11 2015 1993 2001
44. S. Pungpapong, B. Aqel, M. Leise, K.T. Werner, J.L. Murphy, T.M. Henry, and et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant Hepatology 61 2015 1880 1886
45. M. Charlton, G.T. Everson, S.L. Flamm, P. Kumar, C. Landis, R.S. Brown Jr, and et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease Gastroenterology 149 3 2015 649 659
46. M. Buti, J. Llaneras, M. Riveiro-Barciela, and R. Esteban Therapy for hepatitis C genotype 3: moving forward J Viral Hepat 22 9 2015 683 690
47. S. Yoshimi, M. Imamura, E. Murakami, N. Hiraga, M. Tsuge, Y. Kawakami, and et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy J Med Virol 87 11 2015 1913 1920